Vantage logo

The bubble bursts for Proteostasis

Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to. 

Vantage logo

Keytruda wins 2018’s biggest sales upgrade

Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…